Elmind Capital LP purchased a new stake in MBX Biosciences, Inc. (NASDAQ:MBX - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 91,000 shares of the company's stock, valued at approximately $5,023,200. MBX Biosciences makes up about 0.0% of Elmind Capital LP's holdings, making the stock its 20th biggest position. Elmind Capital LP owned about 0.19% of MBX Biosciences at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of MBX. State of Wyoming purchased a new stake in MBX Biosciences in the 2nd quarter valued at $58,000. Russell Investments Group Ltd. boosted its holdings in MBX Biosciences by 4,131.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company's stock worth $26,000 after buying an additional 1,446 shares during the period. Royal Bank of Canada lifted its position in MBX Biosciences by 59.6% in the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company's stock worth $49,000 after buying an additional 572 shares during the last quarter. Strs Ohio lifted its holdings in MBX Biosciences by 128.6% during the first quarter. Strs Ohio now owns 1,600 shares of the company's stock worth $48,000 after buying an additional 900 shares during the period. Finally, California State Teachers Retirement System increased its holdings in MBX Biosciences by 64.7% in the 4th quarter. California State Teachers Retirement System now owns 1,754 shares of the company's stock worth $55,000 after buying an additional 689 shares during the period.
MBX Biosciences Stock Performance
NASDAQ MBX traded down $2.55 during mid-day trading on Friday, reaching $63.84. 220,490 shares of the stock were exchanged, compared to its average volume of 669,362. The business's 50 day moving average is $61.40 and its 200-day moving average is $42.85. The company has a market capitalization of $3.07 billion, a P/E ratio of -26.49 and a beta of 0.10. MBX Biosciences, Inc. has a 1 year low of $9.63 and a 1 year high of $72.64.
MBX Biosciences (NASDAQ:MBX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.10). Equities analysts predict that MBX Biosciences, Inc. will post -3.11 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on MBX shares. Wall Street Zen cut MBX Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Barclays restated an "overweight" rating and issued a $88.00 price objective on shares of MBX Biosciences in a report on Friday, August 7th. Mizuho raised their target price on MBX Biosciences from $57.00 to $91.00 and gave the company an "outperform" rating in a research note on Wednesday, July 29th. UBS Group reaffirmed a "buy" rating and issued a $90.00 price objective on shares of MBX Biosciences in a research report on Thursday, July 23rd. Finally, Citizens Jmp raised their price target on shares of MBX Biosciences from $76.00 to $86.00 and gave the stock a "market outperform" rating in a report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $77.00.
Read Our Latest Stock Analysis on MBX Biosciences
MBX Biosciences Profile
(
Free Report)
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.
Featured Articles
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider MBX Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.
While MBX Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
